Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 9...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Int J Mol Sci
Main Authors: Kanda, Tatsuo, Yasui, Shin, Nakamura, Masato, Suzuki, Eiichiro, Arai, Makoto, Ooka, Yoshihiko, Ogasawara, Sadahisa, Chiba, Tetsuhiro, Saito, Tomoko, Haga, Yuki, Takahashi, Koji, Sasaki, Reina, Wu, Shuang, Nakamoto, Shingo, Tawada, Akinobu, Maruyama, Hitoshi, Imazeki, Fumio, Kato, Naoya, Yokosuka, Osamu
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5454819/
https://ncbi.nlm.nih.gov/pubmed/28441362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18050906
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים